Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 2, 2012, Pages 326-336

  Moore, Amelia E B ^a   Blake, Glen M ^a   Taylor, Kathleen A ^b   Ruff, Valerie A ^b   Rana, Asad E ^b   Wan, Xiaohai ^b   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

99mTc MDP bone scan; Bone remodelling; Bone turnover markers; Osteoporosis; Teriparatide

Indexed keywords

MEDRONIC ACID; PARATHYROID HORMONE[1-34]; RADIOISOTOPE; TECHNETIUM 99M;

AGED; ARTICLE; BONE SCINTISCANNING; BONE TURNOVER; CALVARIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; LEG; MANDIBLE; OSTEOPOROSIS; PELVIS; PLASMA CLEARANCE; SPINE;

AGED; BONE AND BONES; BONE DENSITY; BONE REMODELING; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; TECHNETIUM TC 99M MEDRONATE; TERIPARATIDE; TIME FACTORS; WHOLE BODY IMAGING;

EID: 84859633986     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1974-y     Document Type: Article

References (29)

1. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975;16:744-55.
2. Gnanasegaran G, Cook GJ, Fogelman I. Radionuclide scintigraphy in metabolic bone disease. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington: American Society for Bone and Mineral Research; 2008. p. 166-9.
3. Cook GJ, Gnanasegaran G, Chua S. Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors. Semin Nucl Med 2010;40:52-61.
4. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978;19:270-5. (Pubitemid 8305106)
5. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med 1997;24:1284-90. (Pubitemid 27477622)
6. Scillitani A, Dicembrino F, Chiodini I, Minisola S, Fusilli S, Di Giorgio A, et al. Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int 2002;13:829-34. (Pubitemid 36336729)
7. Moore AE, Blake GM, Fogelman I. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med 2008;49:375-82. (Pubitemid 351355202)
8. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
9. Bone health and osteoporosis: a report of the Surgeon General. Available at: www.surgeongeneral.gov/library/bonehealth. Accessed 20 May 2011.
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. (Pubitemid 32402100)
11. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez- Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17. (Pubitemid 36008334)
12. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. (Pubitemid 350106710)
13. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8. (Pubitemid 41138965)
14. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70. (Pubitemid 40712820)
15. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785-90. (Pubitemid 46141234)
16. Chen P, Miller PD, Recker R, Resch H, Ranan A, Pavo I, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007;22:1173-80. (Pubitemid 351339699)
17. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005;90:3970-7. (Pubitemid 41058159)
18. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41. (Pubitemid 37377441)
19. Glover SJ, Eastell R, McCloskey EV, Rogers A, Gamero P, Lowery J, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009;45(6):1053-8.
20. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-53. (Pubitemid 40863814)
21. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:855-64. (Pubitemid 43787992)
22. Lim GC, Wafa WS, Moses AM. Increased focal uptake of Tc-99m labelled MDP on bone scan suggestive of hyperostosis frontalis interna in a patient being treated with teriparatide. J Bone Miner Res 2005;20 Suppl 1:S174.
23. Mapa J, Conte S, Greene L. Teriparatide-induced Paget's disease of bone. J Bone Miner Res 2009;24 suppl 1:S464.
24. Moore AE, Blake GM, Taylor KA, Rana AE, Wong M, Chen P, et al. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res 2010;25:960-7.
25. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: WHO; 1994. Technical report series no. 843.
26. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89. (Pubitemid 28486716)
27. Jonsson L, Ljungberg M, Strand SE. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med 2005;46:1679-86. (Pubitemid 46211591)
28. Moore AE, Hain SF, Blake GM, Fogelman I. Validation of ultrafiltration as a method of measuring free 99mTc-MDP. J Nucl Med 2003;44:891-7. (Pubitemid 39663399)
29. Patel R, Blake GM, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 2000;11:68-75. (Pubitemid 30099513)